BRW: 9 Hot Tech Stocks
31 May 2012
BRW Journalist Tony Featherstone profiled Starpharma as the #1 pick of the leading ASX tech stocks in his article, ‘9 hot tech stocks.
The Melbourne-based company is leading a pack of promising biotechs either in, or approaching, phase III trials for US Food and Drug Administration approval. Starpharma’s lead product, VivaGel, is being developed to treat bacterial vaginosis, where the normal balance of bacteria in the vagina is disrupted by an overgrowth of certain bacteria. If approved, VivaGel, a prescription product, would be applied daily to treat bacteria vaginosis and stop it reoccurring.
This document contains Forward Looking Statements